Nav: Home

How personalization and machine learning can improve cancer outreach ROI

March 24, 2020

Researchers from Texas A&M, Iowa State University, Rice, and University of Texas Southwestern Medical Center published a new paper in the Journal of Marketing, which examines the efficacy of patient marketing.

The study, forthcoming in the May issue of the Journal of Marketing, is titled "Improving Cancer Outreach Effectiveness Through Targeting and Economic Assessments: Insights from a Randomized Field Experiment" and is authored by Yixing Chen, Ju-Yeon Lee, Shrihari Sridha, Vikas Mittal, and Amit G. Singal.

In 2018, over 1.7 million new cases of cancer were diagnosed in the United States and the cost of cancer care surpassed $147 billion. Many of these cases could have been prevented through regular cancer screening tests that open the door for early detection, more cost-effective treatment options, and better recovery prognosis. For example, regular screening reduces mortality rates for lung cancer by 28%, breast cancer by 24%, and liver cancer by 37%. Moreover, cancer screening can reduce the annual treatment cost for a patient by nearly $5,000.

Healthcare institutions rely on marketing interventions--or direct-to-patient outreach--to increase screening completion among at-risk patients. As an example, Johns Hopkins Hospital's cancer center uses emails, letters, seminars, and community events to encourage screening completion among patients. Yet, according to a recent article in the LA Times, "just 4.2% of patients in the United States who are at high risk for lung cancer get screened for it -- a figure seen as alarmingly low by those who work in the area of prevention." Could it be that the 1.7 million outreach interventions launched in 2015 and $123 million spent on prevention and education efforts go to waste?

The research team used a multi-period randomized field experiment with at-risk patients for hepatocellular carcinoma (HCC), the most common type of primary liver cancer. Patients were randomly assigned (1:1:1) to three different conditions--usual care, outreach alone, or outreach with patient navigation. Usual care is the baseline condition where physicians offer preventive care recommendations at their discretion during a patient's usual care visits. Outreach alone and outreach with patient navigation provide two different levels of direct marketing efforts based on outreach mails, outreach calls, and customized motivational education by trained patient navigators. Patients' demographics, health status, visit history, health system accessibility, neighborhood socioeconomic status, and prior screening compliance were included in the data.

By using causal forests, a state-of-the-art development in machine learning, the researchers discovered that the effectiveness of outreach programs varies widely over time and across patients. For example, outreach programs in general are more effective for patients who are female, minority, in better health status, have a more frequent visit history, covered by medical-assistance insurance, reside in closer proximity to clinics, and reside in a more populated neighborhood. Outreach alone is more effective for patients who are younger, commute faster, and reside in a neighborhood with more public insurance coverage. In contrast, outreach with patient navigation is more effective for patients who are older and reside in a higher-income neighborhood.

By using these patient-level differences in their responsiveness to outreach interventions and a well-established scheme of cost-benefit calculation, the study shows that a targeted outreach program that matches each patient to the optimal outreach type improves the return on the outreach program by 74%-96%, resulting in a gain of $1.6 million to $2 million.

This research helps healthcare practitioners in the following ways:
  • It provides an understanding of how outreach effectiveness varies over time and by patient characteristics that are theoretically relevant and easily accessible to practitioners in their patient database.
  • It offers a cost-benefit analysis approach for assessing individual-level return on marketing investments in the context of liver cancer screening outreach.
  • It offers a tool to recommend the most suitable intervention for each patient.
The research combines the well-known marketing principle that all customers are different with advanced machine learning to show that personalized cancer outreach can save both lives and money.

In mid-March, the author team presented their research in a live webinar where they discussed the methodology. The authors even extrapolated how their research may be used to promote testing for viruses like COVID-19. An on-demand recording is available for free at
Full article and author contact information available at:

About the Journal of Marketing

The Journal of Marketing develops and disseminates knowledge about real-world marketing questions useful to scholars, educators, managers, policy makers, consumers, and other societal stakeholders around the world. Published by the American Marketing Association since its founding in 1936, JM has played a significant role in shaping the content and boundaries of the marketing discipline. Christine Moorman (T. Austin Finch, Sr. Professor of Business Administration at the Fuqua School of Business, Duke University) serves as the current Editor in Chief.

About the American Marketing Association (AMA)

As the largest chapter-based marketing association in the world, the AMA is trusted by marketing and sales professionals to help them discover what's coming next in the industry. The AMA has a community of local chapters in more than 70 cities and 350 college campuses throughout North America. The AMA is home to award-winning content, PCM® professional certification, premiere academic journals, and industry-leading training events and conferences.

American Marketing Association

Related Lung Cancer Articles:

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.
Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
More Lung Cancer News and Lung Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Sound And Silence
Sound surrounds us, from cacophony even to silence. But depending on how we hear, the world can be a different auditory experience for each of us. This hour, TED speakers explore the science of sound. Guests on the show include NPR All Things Considered host Mary Louise Kelly, neuroscientist Jim Hudspeth, writer Rebecca Knill, and sound designer Dallas Taylor.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

Kittens Kick The Giggly Blue Robot All Summer
With the recent passing of Ruth Bader Ginsburg, there's been a lot of debate about how much power the Supreme Court should really have. We think of the Supreme Court justices as all-powerful beings, issuing momentous rulings from on high. But they haven't always been so, you know, supreme. On this episode, we go all the way back to the case that, in a lot of ways, started it all.  Support Radiolab by becoming a member today at